Flaxseed in Controlling Blood Pressure of Patients
Primary Purpose
Hypertension
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Flax Oil Capsule
Placebo Soya Oil Capsule
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Age of the patient above 18 years.
- Patients who agree to take only physician advised medicine.
- Patient who strictly follow diet as advised.
- Patients taking single antihypertensive drug with equivalent doses.
Exclusion Criteria:
- Patient suffering from serious or recurrent infections.
- Pregnancy or breast feeding women, immunodeficiency or HIV patient.
- Patient with finding of any mental abnormality, which would interfere with or be affected by the study procedure .
- Patient with history of bleeding disorders.
- Hypersensitivity reaction or allergy to flaxseed.
- History of surgery within past 6 weeks
- Patient who do not will to give informed consent.
- Alcohol consumption > 30 U/day..
- Cigarette smoking > 2 pack/day
- Patients taking multiple antihypertensive drugs.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
500 mg BD Flax Oil Capsule with Antihypertensive drug
Placebo(Soya Oil) Capsule with Antihypertensive drug
Arm Description
Flax Oil Capsule 500 mg twice a day will be administered alongside antihypertensive drug in newly diagnosed hypertensive subjects
No flax oil capsule,only placebo(soya oil) capsule will be administered alongside equivalent antihypertensive drug in newly diagnosed hypertensive subjects.
Outcomes
Primary Outcome Measures
Flaxseed and Blood Pressure
Assessing the effects of Flaxseeds in systolic and diastolic blood pressure of patients taking antihypertensive drugs
Secondary Outcome Measures
Full Information
NCT ID
NCT04759508
First Posted
February 9, 2021
Last Updated
July 19, 2021
Sponsor
B.P. Koirala Institute of Health Sciences
1. Study Identification
Unique Protocol Identification Number
NCT04759508
Brief Title
Flaxseed in Controlling Blood Pressure of Patients
Official Title
" Effects of Flaxseed in Blood Pressure of Patients Taking Anti Hypertensive Drugs- A Double Blinded Placebo Controlled Randomized Trial."
Study Type
Interventional
2. Study Status
Record Verification Date
July 2021
Overall Recruitment Status
Unknown status
Study Start Date
August 15, 2021 (Anticipated)
Primary Completion Date
September 15, 2021 (Anticipated)
Study Completion Date
October 15, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
B.P. Koirala Institute of Health Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Hypertension is one of the major risk factor for global mortality. Approximately half of 17 million cardiovascular deaths worldwide are accounted for HTN. Multiple research for cost-effective medication for management of hypertension is going on. An effective alternative to medications in managing hypertension is through lifestyle modifications. Adopting healthy diet is a valuable strategy. Randomized controlled year-long trials observed impressive reductions in blood pressure in patients with hypertension consuming flaxseed daily. Therefore, attention has been garnered for flaxseed as a potentially valuable strategy for the management of hypertension. Double blinded, 2 parallel-group, prospective interventional randomized clinical trial. Investigators are planning to conduct most common and basic method of randomization i.e,"lottery method". This is most popular method and simplest method. In this method both Interventional and Placebo groups are numbered on separate slips of paper of same size, shape and color. They are folded and mixed up in a drum or a box or a container. A blindfold selection is made. Required numbers of slips are selected for the desired sample size. The selection of items thus depends on chance. The respective groups are then allocated in a sequence as Code A and Code B that will be concealed from the researcher (JR) enrolling and assessing participants in sequentially numbered, opaque, sealed and stapled envelope. After getting clearance from IRC, randomization will be done where Interventional and placebo groups will be given Flaxseed Capsule 500 mg and Look-alike(Placebo) Capsule with no therapeutic effect respectively twice a day along with equivalent anti-hypertensive drugs in Medicine OPD,BPKIHS. Blood pressure of all the enrolled subjects will be taken on first day of enrollment before start of intervention. After which subjects will be given respective capsules for first 30 days then follow-up. Assigned with respective arms,subjects will be followed up on 90th day. The proforma which includes patient's sociodemographic data,BP value,Adverse Drug reactions and drug interactions will be filled and data will be entered in MS-Excel subsequently and SPSS v11.5 will be used for further analysis. Investigators are planning to conduct a clinical trial in between 2 groups using power and sample size programme. Investigators need to enroll 36 subjects in each group, to be able to reject null hypothesis that means of two different groups are equal with probability of power 95% and at 5% level of significance. Hence sample size is taken 36 in each group. 10% increment will be done in each group if the subject will not come for follow up. Clinically diagnosed hypertension attending medicine OPD, BPKIHS, Dharan, satisfying the inclusion and exclusion criteria and willing to participate in the study will be enrolled. Prior to the conduction of the study ,ethical clearance will be obtained from the Institutional Review Committee(IRC) of BPKIHS and the clinical trial will be registered. Precaution will also be taken as far as possible to avoid pain and suffering and side effects of the medication to the subjects during the course of the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
72 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
500 mg BD Flax Oil Capsule with Antihypertensive drug
Arm Type
Active Comparator
Arm Description
Flax Oil Capsule 500 mg twice a day will be administered alongside antihypertensive drug in newly diagnosed hypertensive subjects
Arm Title
Placebo(Soya Oil) Capsule with Antihypertensive drug
Arm Type
Placebo Comparator
Arm Description
No flax oil capsule,only placebo(soya oil) capsule will be administered alongside equivalent antihypertensive drug in newly diagnosed hypertensive subjects.
Intervention Type
Dietary Supplement
Intervention Name(s)
Flax Oil Capsule
Intervention Description
Flaxseed with brand name Flax Oil Capsule will be administered to subjects receiving antihypertensives.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo Soya Oil Capsule
Intervention Description
Placebo capsule filled with soya oil and inert(inactive) substances will be administered to subjects remaining anti hypertensives.
Primary Outcome Measure Information:
Title
Flaxseed and Blood Pressure
Description
Assessing the effects of Flaxseeds in systolic and diastolic blood pressure of patients taking antihypertensive drugs
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age of the patient above 18 years.
Patients who agree to take only physician advised medicine.
Patient who strictly follow diet as advised.
Patients taking single antihypertensive drug with equivalent doses.
Exclusion Criteria:
Patient suffering from serious or recurrent infections.
Pregnancy or breast feeding women, immunodeficiency or HIV patient.
Patient with finding of any mental abnormality, which would interfere with or be affected by the study procedure .
Patient with history of bleeding disorders.
Hypersensitivity reaction or allergy to flaxseed.
History of surgery within past 6 weeks
Patient who do not will to give informed consent.
Alcohol consumption > 30 U/day..
Cigarette smoking > 2 pack/day
Patients taking multiple antihypertensive drugs.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rakesh Verma, MBBS, MD
Phone
9812560610
Email
tipparv@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rakesh Verma, MBBS, MD
Organizational Affiliation
B.P. Koirala Institute of Health Sciences
Official's Role
Principal Investigator
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Individuals enrolled in the respective arms will be shared
IPD Sharing Time Frame
Starting February 15,2021
IPD Sharing Access Criteria
Assess granted to sponsor, study team and data steward
Citations:
PubMed Identifier
24126178
Citation
Rodriguez-Leyva D, Weighell W, Edel AL, LaVallee R, Dibrov E, Pinneker R, Maddaford TG, Ramjiawan B, Aliani M, Guzman R, Pierce GN. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Hypertension. 2013 Dec;62(6):1081-9. doi: 10.1161/HYPERTENSIONAHA.113.02094. Epub 2013 Oct 14.
Results Reference
background
Learn more about this trial
Flaxseed in Controlling Blood Pressure of Patients
We'll reach out to this number within 24 hrs